Pretreatment with rosiglitazone, which promotes placental synthesis of peroxisome proliferator-activated receptor-γ (PPARγ) similarly attenuates responsiveness to LPS-induced PTD, in association with suppressed NFκB signaling and reduced synthesis of TNF, IL1, IL6 and other pro-inflammatory chemokines57. The gene discussed is IL1A; the disease is Bjornstad syndrome.